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The Role of Ghrelin and Leptin in Obesity:





 Ghrelin and leptin are two hormones that have been recognized to have a major influence 
on energy balance. Leptin is a mediator of long term regulation of energy balance, suppressing 
food intake and thereby inducing weight loss. Ghrelin, on the other hand, is a fast acting hormone, 
playing a role in meal initiation. As a growing number of people suffer from obesity, understand-
ing the mechanisms by which various hormones and neurotransmitters influence energy balance 
has been a subject of intense research. This paper provides background on leptin and ghrelin 
hormones, their role in food intake and body weight in humans, and their mechanism of action. 
Possible abnormalities in the leptin and ghrelin systems that may contribute to the development of 
obesity will be mentioned. The role of gut hormones on hunger and satiety as well as the effect of 
sleep deprivation on these hormones will be briefly described. Finally, the potentials of leptin and 
ghrelin as drug targets will be described (Klok, et al., 2006). 
INTRODUCTION
 
 The incidence of obesity has increased dramatically worldwide. The prevalence of obesity 
is a major health problem because excessive body weight is a risk factor for development of chron-
ic diseases such as cardiovascular disease and type II diabetes mellitus (Park, 2010). Overweight 
is a result of a deregulation of calorie intake and energy expenditure. An individual’s genetics and 
the environment create a system that controls appetite and energy expenditure. Throughout the 
past few decades the type and cost of food has changed. The food industry encourages people to 
eat fast foods which are relatively inexpensive but high in calories. Snacks and beverages high in 
sugar have also been added to the daily diet. Physiologically, the body secretes hormones which 
are responsible for controlling appetite and satiety. Genetic defects in this control system manifest 
itself in obesity (Skelton & Rudolph, 2007). The overwhelming percentage of overweight people 
created the need to develop new treatments. In pursuit of this goal, researchers have dissected 
the mechanism through which satiety and hunger manifests (Jayasena & Bloom, 2008). Further 
research has led to the discovery of gut hormones and the role of adipose tissue as participants in 
controlling the body’s physiologic and pathologic processes (De Luis, et al., 2008).
 Body weight is regulated by a complex system. Two hormones that play an important role 
in the regulation of food intake and body weight are leptin and ghrelin. Both hormones are part of 
the peripheral nervous system and signal the brain, specifically the arcuate nucleus (ARC) of the 
hypothalamus, through different pathways. In the hypothalamus, activation of leptin and ghrelin 
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receptors set off different signals leading to changes in food intake (Klok, et al., 2006). One of the 
pathways consists of neurons that express neuropeptide Y (NPY) and agouti gene related protein 
(AgRP), stimulators of food intake. Other arcuate neurons express proopiomelanocortin (POMC), 
cocaine and amphetamine- regulated transcript (CART), which suppress food intake (Nogueiras, 
et al., 2004).
DISCUSSION
Leptin and its Functions
  The human obese (OB) gene and its product leptin were discovered in 1994. The OB gene 
is on chromosome 7 (Klok, et al., 2006). It encodes leptin, a protein consisting of 167 amino ac-
ids which is secreted primarily from adipocytes. Leptin is also secreted by skeletal muscles, the 
placenta, and the stomach (Feldman,Freidman, & Brandt, 2010). Leptin acts through the leptin 
receptor (OBR). The OBR gene is located on the first chromosome and encodes a protein consist-
ing of 1162 amino acids. OB-Rb, a part of the OBR gene, is expressed in the hypothalamus and 
the cerebellum. Leptin functions through a feedback mechanism that signals regulatory centers in 
the brain to inhibit food intake and to regulate body weight and energy homeostasis (Klok, et al., 
2006). Studies on rodents have shown that the hypothalamus is the primary center for body weight 
and food intake regulation. After leptin is released by adipose tissue, it crosses the blood brain 
barrier and binds to the hypothalamic leptin receptors, conveying information regarding the status 
of body energy stores. Leptin inhibits the expression of orexigenic, or appetite stimulating neuro-
peptides, and stimulates anorexigenic, or appetite inhibiting neuropeptides in the arcuate nucleus 
of the hypothalamus (Neary, et al., 2003).   





 When leptin is secreted, it activates anorexigenic peptides proopiomelanocortin and co-
caine and amphetamine-regulated transcript neurons and inhibits orexigenic peptides neuropeptide 
Y and agouti-related protein neurons which results in inhibition of eating and an increase in energy 
expenditure (Nogueiras, et al., 2004). 
 Leptin is involved in different signaling pathways in the hypothalamus.  Leptin is a mem-
ber of the cytokine family of signaling molecules. There are different forms of leptin receptors 
throughout the body. The “long form” leptin receptor is a type of cytokine-receptor, which is 
located in the hypothalamic nuclei. Leptin binds to and activates Janus Kinase (JAK-2), tyrosine 
kinases involved in intracellular cytokine signaling, beginning a positive feedback mechanism. 
Activation of JAK-2 leads to phosphorylation of members of the signal transduction and transcrip-
tion family of proteins (STAT). As a result, STAT proteins activate transcription of leptin target 
genes (Figure 2). The “long form” of leptin receptor is required for normal energy homeostasis. 
Studies have shown that mutations of this gene result in obesity in rodents (Kronenberg, et al., 
2008)
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Figure 2. The Pathway of leptin through a positive feedback mechanism
 
 
 Leptin also activates other pathways in the hypothalamus.  Leptin activates the insulin 
receptor substrate phosphatidylinositol-3 OH kinase (IRS PI 3-Kinase) pathway in the hypothala-
mus which is also required for leptin regulation of food intake. Leptin also increases hypothalamic 
mammalian target of rapamycin (mTOR) activity, an enzyme which regulates growth.  This path-
way is required for leptin-induced anorexia, or lack of appetite. Signaling through these pathways 
in the hypothalamus is necessary for leptin to function to reduce food intake and body weight. 
 In addition, the “long form” of leptin receptor is expressed in the hippocampus, hindbrain, 
and mesolimbic areas. The mesolimbic areas are involved in reward and include the ventral teg-
mental area (VTA) and the substantia nigra. This leads to the possibility that leptin may reduce 
food intake through direct action on brain motivation/reward circuitry, in addition to the action of 
leptin on areas of the brain involved with energy homeostasis (Morton, et al., 2009). 
 A study was performed to examine the mechanism by which leptin signaling in the VTA 
reduces food intake (Morton, et al., 2009). Two questions arose: Firstly, does leptin activate the 
Janus Kinase - signal transduction and transcription family of proteins, insulin receptor substrate 
phosphatidylinositol-3 OH kinase, and hypothalamic mammalian target of rapamycin signal trans-
duction pathways in the ventral tegmental area and substantia nigra as it does in the hypothalamus? 
Secondly, is activation of these pathways required for VTA leptin-induced anorexia? The data col-
lected suggested that JAK-2 signaling in the ventral tegmental area is activated by leptin. JAK-2 
is required for anorexia induced by VTA leptin action, but leptin signaling of IRS-PI 3-kinase and 
mTOR do not participate in ventral tegmental area leptin induced anorexia. 
Leptin binds to and activates
Janus Kinase
Phosphorylation of members of the signal
transduction and transcription family of
proteins (STAT).
STAT proteins activates transcription of
leptin target genes
62
 The experiment was performed on adult male Wistar rats held in a temperature controlled 
room and provided with ad libitum access to water and food. A stainless steel cannula was placed 
in the third cerebral ventricle in the animals to examine the signal transduction pathways activated 
by intracerebroventricular administration of leptin. In experiments with intra ventral tegmental 
area injections, a bilateral stainless steel cannula was implanted to the ventral tegmental area. The 
rats had 7 days to recover after the surgery, and daily intake of food and body weight was recorded. 
An hour before the injection of recombinant mouse leptin into the VTA, the food was removed. A 
dosage of 0.05, 0.25, or 0.50 micrograms was administered. To determine the role of JAK-STAT 
signaling in VTA leptin action, the leptin injection was counterbalanced with either a pretreatment 
of JAK-2 inhibitor or, as a control, its vehicle (a substance of no therapeutic value used to convey 
an active medicine for administration).
  It had been demonstrated previously that this inhibitor blocks the central effect of leptin to 
reduce food intake and body weight. The food was then replaced. Similar injections were admin-
istered to determine the role of insulin receptor substrate phosphatidylinositol-3 OH kinase and 
hypothalamic mammalian target of rapamycin on leptin action in the ventral tegmental area. 
 The results showed that bilateral intra VTA leptin administration in rats reduced food in-
take by 25%. The reduction of food intake was accompanied with a decrease in body weight in the 
animals that received leptin as opposed to the control group. In the case of the JAK-STAT pathway, 
it was found that central administration of leptin activated the JAK-STAT pathway in the ventral 
tegmental area and the substantia nigra. To determine if leptin acts directly in the VTA to activate 
the pathway, leptin was delivered directly into the VTA. It was noted that intra-VTA administration 
of leptin induced tyrosine phosphorylation of STAT3, a mediator of leptin receptor signaling in 
this part of the brain. However, intra-VTA pretreatment of the JAK-2 inhibitor, when administered 
alone blocked leptin in the VTA from reducing food intake and decreasing body weight. 
 The experiment continued to determine whether leptin in the VTA signals through the IRS-
PI 3-Kinase pathway. The question to address was, does intracerebroventricular leptin or direct ad-
ministration of leptin in the ventral tegmental area increase phospho protein kinase B, a marker of 
PI 3-Kinase activation? The result was that leptin administration failed to induce phospho protein 
kinase B in the VTA. An additional group of rats was used to determine if the mTOR pathway is 
affected by leptin action in the VTA. Neither intracerebroventricular nor direct intra-ventral teg-
mental area administration of leptin activated the mTOR signaling pathway in the VTA.  Although 
the hypothalamus plays a major role in leptin signaling and activation, this experiment supports the 
growing body of evidence that leptin receptors are expressed in extrahypothalamic sites as well, 
particularly the VTA (Morton, et al., 2009). 
Leptin and Obesity
 Researchers suggest that obesity in humans is due to leptin resistance. Leptin resistance is 
thought to involve a period of overeating. Overeating results in an increase in leptin levels, which 
may damage the hypothalamus. As a result, the hypothalamus becomes less sensitive to leptin, 
leading to a sustained increase in leptin levels (Klok, et al., 2006). 
The Role of Ghrelin
 Ghrelin plays a central role in weight regulation.  In 1999, attempts to identify the endoge-
nous ligand for the growth hormone secretagogue receptor (GHS-R) led to the discovery of ghrelin 
(Higgins, et al., 2007). The gene that codes for human prepro-ghrelin is located on chromosome 3. 
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Prepro-ghrelin consists of 117 amino acids, and the mature ghrelin constitutes 28 amino acids, with 
a fatty acid chain on the third amino acid. Ghrelin peptide was first isolated in the stomach and is 
most abundant in the gastric fundus, but is also found in the pancreas and adrenal cortex. Ghrelin 
is produced by endocrine cells known as P/D1 cells that are categorized as opened or closed. The 
open cells are exposed to the lumen of the stomach and are in contact with gastric contents. The 
closed type is in close proximity to the capillary network of the lamina propria. Both types of cells 
secrete the hormone into the bloodstream (Feldman, et al., 2010). In the brain, ghrelin producing 
neurons are found in the pituitary, hypothalamic arcuate nucleus, and between the dorsal, ventral, 
paraventricular, and arcuate hypothalamic nucleus (Klok, et al., 2006). 
 Ghrelin stimulates growth hormone secretion, increases food intake, and produces weight 
gain. Ghrelin is a member of the motilin family of peptides, stimulates gastric contraction and 
enhances stomach emptying (Feldman, et al., 2010).  Ghrelin levels show preprandial (prior to 
meals) increase and postprandial (after meals) decreases. Ghrelin levels are also low in obesity, 
while high during fasting and in anorexia nervosa. The postprandial reduction of ghrelin levels is 
smaller in obese subjects than in subjects of normal weight. This explains how ghrelin leads to 
excessive eating. First, the diminished reduction of postprandial ghrelin levels increases the length 
of time that subjects feel hungry. Second, because of relatively higher ghrelin levels, the speed of 
gastric emptying may not be reduced, which causes a lack of feeling satisfied. Without feelings of 
satiety, obese individuals eat more than they need and gain weight. Furthermore, ghrelin levels are 
influenced by age, gender, BMI, growth hormone, glucose, and insulin. Leptin also affects ghrelin 
levels. Ghrelin plays a central role in neurohormonal regulation of food intake and energy homeo-
stasis. 
 The expression of orexigenic peptides in the hypothalamus regulates eating behavior. Obe-
sity may develop from deregulation of these pathways. Intravenous and central administration of 
ghrelin stimulates hunger and food intake. Ghrelin levels are decreased in obese subjects, which 
are thought to be the body’s response to reduce hunger and food intake in those with excessive 
energy balance. 
 In the following study, the diets of healthy lean men were supplemented with a moderate 
amount of fat-rich food, to establish the effect of overfeeding on plasma ghrelin levels. Six men 
between the ages 21-34 with a BMI of 21.4-24.3 were included in the study. Over a period of three 
weeks, the participating students visited the lab for 8 experimental visits, 4 visits for postprandial 
fat loading tests and 4 visits for the measurement of gastric emptying. The day before postprandial 
testing, subjects were given a low fat dinner, and refrained from exercise. The day of the testing, 
an oral fat tolerance test consisting of 125 ml of dairy cream was administered and blood samples 
were taken at 30 minute intervals for 2 hours and then at 4 and 6 hours postprandially. The same 
preparation was done the day before gastric emptying measurement: a low fat dinner, and no 
exercise the night before. In the morning of the testing, subjects consumed 500 ml of water. A na-
sogastric tube was positioned. A 300 ml intralipid was injected into the stomach over a period of 
2 minutes. The contents of the stomach were mixed by aspiration and 20-30 ml was reinjected 10 
times using a catheter tip syringe. This cycle continued for 60 minutes. Following the initial tests, 
subjects were provided with a high fat dietary supplement to be eaten daily for 3 weeks. Subjects 
were tested on days 7, 14, and 21 for postprandial testing, and on days 8, 15, and 22 for gas-
tric emptying measurements. Blood samples were collected to analyze plasma fatty acids, leptin, 
ghrelin, and pancreatic polypeptide. During the study, the mean weight gain was 2.1 kg. Results 
showed that the inhibitory response of ghrelin to oral fat was enhanced after overfeeding. Before 
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the study, maximal suppression of ghrelin occurred 90 minutes postprandially. After only one 
week into the study, the maximal suppression occurred at 120 minutes. Leptin concentration was 
increased after the 3 week dietary supplementation. Triglyceride concentration was also changed 
by dietary supplementation. It has been suggested that ghrelin levels respond to changes in body 
weight and not to changes in energy supplied to the GI tract. However, these results imply that 
changes in ghrelin concentration begin before significant increases in body weight, since a weight 
gain of 3% was associated with an 18% decrease in ghrelin concentration in the study. 
The Mechanism of Action of Ghrehlin
 Ghrelin is considered a natural growth hormone secretagogue (GHS), or a substance that 
stimulates the secretion of growth hormone.  Generally, the administration of growth hormone 
secretagogues, which are synthetic peptide and nonpeptide compounds, stimulates the release of 
growth hormone.  Administration of growth hormone secretagogues synthetic peptide also stim-
ulates feeding behavior. Growth hormone secretagogues receptor (GHS-R) is expressed in the 
pituitary gland, hypothalamus, and several other areas. In the hypothalamus, GHS-R mRNA is 
expressed in neuropeptide Y, agouti-related protein, proopiomelanocortin, and growth hormone 
releasing hormone (GHRH) containing neurons. 
 Similarly, research shows that ghrelin administration increases food intake in rodents. An 
experiment was done on male Sprague –Dawley rats, weighing 250-280 grams. They were given 
food and water ad libitum. A stainless steel cannula was implanted into the right lateral ventricle. 
Only the rats whose cerebrospinal fluid flowed into the cannula were used. The rats were injected 
Figure 3. These two diagrams show the result of the above experiment,  
indicating that the primary hypothalamic target of ghrelin are NPY and AGRP, 
proving that ghrelinis an orexigenic peptide (Kamegai, et al., 2001).
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with the peptide 14 days after the cannula was placed. Rat ghrelin or saline was injected every 12 
hours over a 72 hour period. Food intake and body weights were measured daily. Around 4 hours 
after the last ghrelin injection, the rats were killed. The blood was taken to test glucose, insulin, 
leptin, and growth hormone levels. The brains were preserved, and then coronal sections were cut 
and mounted onto slides. The results revealed an increase in food intake; however, they did not 
affect plasma insulin, glucose, leptin, and GH concentrations. Figure 3 shows that neuropeptide 
Y mRNA levels were increased, as well as arcuate nucleus agouti-related protein mRNA levels 
in ghrelin treated rats. However the levels of proopiomelanocortin and growth hormone releasing 
hormone mRNA in the arcuate nucleus did not differ between the ghrelin treated and saline treated 
rats. These results show that the primary hypothalamic targets of ghrelin are neuropeptide Y and 
agouti-related protein neurons and that ghrelin is an orexigenic peptide in the brain and stomach. 
The fact that ghrelin administration did not alter GHRH levels or the release of growth hormone 
indicates that the orexigenic action of ghrelin is not likely to be due to GH secretion (Kamegai, et 
al., 2001).
 In contradiction to this experiment, experiments on Zucker rats led to the conclusion that 
ghrelin may be GH dependent (Nogueiras, et al., 2004). The purpose of this study was to investi-
gate a number of properties affecting ghrelin.  
1. Leptin may alter the expression of Growth hormone secretagogues receptor, thereby 
inhibiting the effect of ghrelin.
2. The effect of leptin administration on the expression of Growth hormone secretagogues 
receptor in the arcuate nucleus and ventromedial nuclei.
3. The influence of ghrelin administration on Growth hormone secretagogues receptor 
expression.
4. The influence of ghrelin on the expression of leptin receptors Ob-Rb.
5. The role of growth hormone in the effect of ghrelin.
 The rats used were male between the ages of 8 and 12 weeks. For short term ghrelin and 
leptin effects, intracerebroventricular cannulas were implanted in the lateral ventricle of the rats. 
One group of rats was fed ad libitum, and the other group was deprived of food for 48 hours. The 
rats were then injected with a single injection of ghrelin or its vehicle. In a second experiment, rats 
were injected with 0.5, 2.0, or 5.0 microgram of rat ghrelin or its vehicle. In both cases, the rats 
were killed 2 hours after the injection. In another experiment, rats were fed ad libitum or fasted 
for 48 hours. A single injection of recombinant human leptin or its vehicle was given, and the ani-
mals were killed 2 hours after. For long term ghrelin effects, a cannula was placed in the lateral 
ventricle. Rats received ghrelin or its vehicle for 24 hours, 48, hours, or 7 days. For leptin testing, 
either human recombinant leptin or its vehicle was infused for a period of 7 days into the lateral 
ventricle. The last 48 hours of the infusion, the rats were either fed ad libitum or fasted. 
 The results showed the following. The GHS-R expression was higher in the arcuate nu-
cleus of the obese Zucker rats than the lean rats, but the expression in the ventromedial nuclei did 
not differ significantly. Plasma ghrelin levels were unchanged in the fatty rats in comparison to the 
lean ones. The GHS-R mRNA of the arcuate nucleus in fasted rats was higher than in ad libitum 
fed rats. No change was seen in its expression in the ventromedial nuclei. 
 The effect of leptin on GHS-R differed for short and long term infusions. A single injection 
of leptin did not affect the level of GHS-R expression in the arcuate nucleus or ventromedial nu-
clei in the fed animals. However, the long term infusion of leptin decreased food intake and body 
weight. Additionally, long term infusion of leptin caused a decrease in GHS-R levels in the ARC 
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but not in the ventromedial nuclei in both ad libitum and fasted animals. The effect of leptin on 
GHS-R was dose dependent. No change was seen at 1 microgram/ day, but at 5 and 15 microgram/
day, GHS-R expression was lower. 
 Ghrelin also had a significant effect on GHS-R expression in the ARC.  After short-term 
treatment with ghrelin, GHS-R mRNA levels increased in the arcuate nucleus. The administration 
of ghrelin caused an increase in food intake. The increase in GHS-R gene expression was also seen 
in the fasting animals. No change was seen in the ventromedial nuclei in any of the treatments. 
The effect of ghrelin seemed to be dose-dependent: gene expression of GHS-R was higher after 5 
micrograms compared with 2 micrograms. In long term infusion of ghrelin, GHS-R mRNA was 
only significantly increased after 1 week and not after 24 hours or 48 hours. 
 Interestingly, short term treatment of ghrelin did not increase GHS-R mRNA levels in the 
arcuate nucleus of growth hormone deficient rats. It was concluded that ghrelin and leptin are both 
involved in the regulation of GHS-R in the arcuate nucleus, but not in the ventromedial nuclei. 
Intracerebroventricular ghrelin increases GHS-R expression while intracerebroventricular leptin 
decreases GHS-R mRNA. During fasting (high levels of ghrelin and low levels of leptin) and 
in obese rats insensitive to leptin, GHS-R mRNA expression is increased in the arcuate nucleus. 
GHS-R mRNA seems to be regulated by ghrelin through a GH dependent mechanism since ghrelin 
fails to stimulate GHS-R expression in the absence of GH (Nogueiras, et al., 2004).
 Ghrelin is released from the GI tract and provides input to the brain through three 
mechanisms. 
1. Directly, via the blood stream, by entering the anterior pituitary gland and other areas of the 
brain not protected by the blood brain barrier.
2. Directly, by crossing the blood brain barrier, via a saturated transport system.
3. Indirectly, via the vagus nerve. Ghrelin levels rise before a meal due to the reduced inhibitory 
controls of the vagus nerve on ghrelin.
 Ghrelin acts in the arcuate nucleus, a part of the brain important in the regulation of feed-
ing and appetite. Growth hormone secretagogues receptors are found in the arcuate nucleus on 
neurons that release neuropeptide Y and agouti-related protein, stimulators of weight gain, where 
ghrelin acts to increase the output from these neurons. GHS can be found on presynaptic nerve 
endings, influencing the release of neurotransmitters. 
 Ghrelin promotes appetite in two ways. It can depolarize the orexigenic neuropeptide Y 
and agouti-related protein neurons, or it can increase the inhibition exerted by the NPY and AgRP 
neurons over the anorexigenic proopiomelanocortin and cocaine and amphetamine-regulated tran-
script neurons. Both of these enhance appetite (Higgins, et al., 2007). Ghrelin stimulates the activ-
ity of neurons expressing neuropeptide Y, agouti related protein, and orexin. On the other hand, 
ghrelin inhibits proopiomelanocortin neurons and corticotrophin releasing hormone producing 
neurons (Figure 4) (Klok, et al., 2006). 
Gherelin and Obesity
 Ghrelin functions as a meal-initiation signal in the system for short term energy balance 
regulation. This is demonstrated by two things. Firstly, the preprandial increase in ghrelin levels 
initiates meals voluntarily even in the absence of food. Secondly, an intravenous injection of ghre-
lin induces hunger and food intake in healthy and obese humans (Klok, et al. 2006). In addition to 
the involvement of ghrelin in short term regulation of energy balance, it also plays a role in long 
term energy balance regulation. Ghrelin concentration is negatively correlated with BMI. Ghrelin 
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levels change in response to dieting to maintain body weight. This is seen in obese and anorexic 
subjects. When obese people lose weight, these levels increase, and they decrease when anorexic 
patients gain weight (Klok, et al. 2006).
 
Gut Hormones and their Effect on appetite 
 Although ghrelin is the only gut hormone that stimulates food intake, there are other hor-
mones in the GI tract that have an effect on hunger and satiety (Jayasena & Bloom, 2008). In 1982, 
Peptide YY (PYY) was isolated from colonic extracts. Peptide YY is a 36 amino acid peptide 
with tyrosine residue at both the C and the N terminals. PYY is secreted from the endocrine L 
cells of the small and large bowel. Two forms of peptide YY exist, PYY 1-36 and PYY 3-36. The 
maximum concentration is found in the rectum, while lower concentrations are found in the small 
intestine, terminal ileum, and colon. In contrast to ghrelin, PYY levels are suppressed in a fasting 
state, but increase after a meal. PYY levels in the body are lowest in the morning, and steadily 
increase throughout the day, reaching a peak after the evening meal (Neary, et al., 2003). Peptide 
YY is released into the blood following a meal, in proportion to the calorie intake. PYY acts on the 
hypothalamus as a satiety signal. It has multiple effects that slow the passage of nutrients through 
the gut. PYY decreases food intake by delaying gastric emptying, and inhibiting gallbladder con-
traction, pancreatic exocrine secretions, and gastric acid secretion (Jayasena & Bloom, 2008.) 
Figure 4. This drawing shows the pathways by which ghrelin and leptin may reach the hy-
pothalamus in order to have an effect on food intake and body weight. Leptin is secreted by 
adipose tissue and ghrelin is secreted by the stomach. Both hormones may enter the brain 
through the bloodstream. In addition, ghrelin and leptin may reach the hypothalamus through 
the vagal nerve and nucleus tractus solitarus. Leptin and ghrelin both stimulate (+) and sup-
press (-) hypothalamic neurons resulting in anorexic or orexic effects on energy balance (Klok, 
et al. 2006).
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Peptide YY reduces the appetite stimulating hormone ghrelin, and diminishes the preprandial rise 
in ghrelin. Low levels of peptide YY in obese subjects point to PYY deficiency contributing to 
obesity (Popovic & Duntas, 2005)
 Another gut hormone involved in the increase or decrease of food intake is cholecystokinin 
(CCK). CCK is a peptide hormone expressed in the small intestine and is released after a meal. 
Cholecystokinin stimulates pancreatic and gallbladder exocrine secretions, inhibits gastric empty-
ing, and increases intestinal mobility. Cholecystokinin also acts as a neurotransmitter. Injections 
of cholecystokinin decrease the amount eaten but increase meal frequency without any change in 
body weight. However, because the ability of cholecystokinin to reduce food intake does not last 
long, it is not the best target as a drug to treat obesity (Jayasena & Bloom, 2008).
Ghrelin and Leptin as Drug Therapy
 Because of the increasing cases of obesity throughout the world, scientists found a need to 
find an effective drug therapy to aid in weight loss. This has led to extensive research on recom-
binant hormones, as well as lipase inhibitors as possible paths to increase or decrease ghrelin and 
leptin as needed.
Current Drug Therapy For Obesity
 Pharmacotherapy options to treat obesity are very limited. There are two weight loss medi-
cations that are approved in the United States and Europe, Orlistat® and Sibutramine®. Very re-
cently, Rimonabant® was approved in some European counties. The FDA recommends pharmaco-
therapy only after dieting and exercise have failed and the BMI is greater than 30kg/m2. Orlistat® 
(Figure 5) was approved by the FDA in 1999.
 Orlistat® is a gastrointestinal lipase inhibitor. It decreases fat absorption by binding to 
pancreatic lipase, which blocks hydrolyses of triglycerides into fatty acids and monoglycerides, 
and increases fat excretion 
in fecal material by 30%. In 
clinical trials, weight loss 
was 3% greater in subjects 
taking Orlistat® compared 
to those taking the placebo. 
Orlistat® has gastrointestinal 
side effects such as oily fecal 
splotting, fecal urgency, abdominal pain, and fecal incontinence. In addition, Orlistat causes a loss 
of fat soluble vitamins. 
 Sibutramine® (Figure 6) was approved by the FDA in 1997.  It inhibits serotonin and 
norepinephrine reuptake. Sibutramine® was originally 
created as an antidepressant and reduces food intake by 
reducing appetite. It has been demonstrated, that long term 
Sibutramine® along with a reduced calorie diet resulted 
in weight loss over a period of 1-2 years. In clinical tri-
als, weight loss was 5% greater in subjects taking Sibutra-
mine® than those taking the placebo. Maximum weight 
loss was achieved after six months, and was dose related. 
10 mg/day resulted with an average of 7.4 kg compared 
 Figure 5. Chemical Structure of Orlistat®  (Isidro & Cordido, 2009).
Figure 6. Chemical structure of sibutramine 
(Isidro & Cordido, 2009).
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with 3.6 kg for the placebo, and 15 mg/day resulted in 10.3 kg weight loss compared with 1.3 kg 
in the placebo group. Because Sibutramine® can increase blood pressure and heart rate, patients 
taking it are monitored carefully.  
 Although these anti obesity drugs do promote weight loss of 3-5% of initial body weight, 
most patients are still overweight or obese after treatment. In addition, they regain the weight lost 
after drug withdrawal. Therefore different strategies are being researched to achieve weight loss, 
such as stimulating anorexigenic signals and blocking orexigenic signals. Possible antiobesity 
therapy currently being investigated includes leptin receptor superagonists, neuropeptide Y recep-
tor antagonists, peptide YY analogues, ghrelin receptor antagonists, and growth hormone receptor 
agonists (Isidro & Cordido, 2009).
 A study was done comparing leptin and ghrelin levels in obese subjects who took Orlistat® 
and those only on a dietary regimen of 55% carbohydrates, 25% each of fat and protein over a span 
of 12 weeks. Twenty-one obese patients, 6 males and 15 females, and ten control subjects were 
involved in the experiment. The obese patients were divided into two groups: one group consist-
ing of 11 people who took Orlistat® 3 times daily, while the second group of 10 received dietary 
treatment only. At the end of the 12 week period, there were decreases in BMI, weight, waist pe-
rimeter, glucose, insulin, and cholesterol in the Orlistat® group, while there was only a decrease 
in BMI, weight, and insulin levels in the dietary treatment group. Ghrelin levels were increased in 
both groups. Leptin levels were reduced in the Orlistat® experimental group, but did not decrease 
significantly in the dietary treatment group. The results of this study have shown that patients who 
change their lifestyle and eating habits have similar success rates as those who are treated with 
Orlistat®. The elevated leptin levels and reduced ghrelin in obesity are reversed by weight loss 
regardless of the type of treatment, Orlistat® vs. dietary treatment (Ozkan, et al., 2009). However, 
the above experiment does not have a proper control and experimental group. The group that was 
given Orlistat® was also on dietary treatment, making it difficult to discern whether the weight 
loss and change in BMI, glucose and insulin levels were due to changes in food habits or to the 
treatment of Orlistat®. 
Leptin As Pharmacotherapy
 Leptin directs the onset and termination of appetite and restraint between meals at two 
sites. At the first site, leptin opposes the orexigenic action of ghrelin directly and indirectly by re-
straining the output of excitatory neuropeptide Y signaling in the arcuate nucleus- paraventricular 
nucleus axis. Secondly, leptin suppresses ghrelin output from gastric glands to restrain appetite be-
tween meals. Deficiency in this complex system of leptin restraint leads to weight gain in humans 
and rodents. Several experiments were performed to try to prevent an insufficiency of leptin with 
the goal that it will assist those with obesity. 
 One experiment was  done with gene transfer technology with viral vectors. The non-repli-
cative, non-immunogenic, and non-pathogenic vector, recombinant adeno-associated viral vector 
encoding the leptin gene was engineered for testing in rodents. It was found that a single intra-
venous injection increased circulating leptin and normalized body weight in obese leptin mutant 
mice. Similar effects were produced when it was injected centrally into either intracerebroven-
tricularly or into hypothalamic sites on leptin mutant rats and mice (Kalra, 2007).
 Another experiment was done to determine whether leptin administration affects body 
weight. As mentioned earlier, leptin signals regulatory centers in the brain to inhibit food intake 
and regulate body weight. Overeating can cause a lack of sensitivity to leptin receptors and signal-
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ing resulting in obesity. This insensitivity is thought to be overcome by administration of exog-
enous recombinant methionyl human leptin in high doses. 
 A previous study had shown that a minimum of 3 injections daily of recombinant leptin 
was required to have an effect; however, this dose was intolerable. Therefore, this study (Zelissen, 
et al., 2005) was done to determine whether a lower dosage of leptin would be tolerated better. The 
recombinant leptin would be injected at night to mimic the normal diurnal rhythms. Diurnal varia-
tion in endogenous leptin peaks between 12:00 and 2:00 AM, and is less pronounced in obese sub-
jects. It was hypothesized that diurnal variation could be improved by recombinant leptin admin-
istered once daily in the evening, which might result in greater weight loss. For 3 weeks, patients 
with a BMI between 27.5 and <37.5 kg/m2  were given a 2100 calorie diet. All participants were 
given 2-ml injections of a placebo. Those that lost more than 5 kg over this period were excluded 
from the rest of the experiment. Patients were divided into three groups of 12 week treatment regi-
mens. 
• Group 1: administered once daily in the morning; 70 patients with recombinant leptin and 25 
with placebo.
• Group 2: administered once daily at night; 70 patients with recombinant leptin and 24   
with placebo.
• Group 3: administered twice daily; 71 patient with recombinant leptin and 24 with placebo.
 The results did not show overall significant changes between the placebo groups and the 
leptin groups. Although only slight, the difference in weight change was greater in the twice daily 
recombinant leptin and placebo than in the once daily doses. The weight loss of subjects with low 
serum leptin levels was not much different from those with high serum leptin levels. Similarly, 
feelings of hunger were compared between the groups, and no change was found. The same was 
true for calorie intake from before the study and the end of the study. Other studies have shown 
that when pegylated leptin was administered in addition to a restricted diet, greater weight loss was 
observed (Zelissen, et al., 2005). As in Ozkan, et al.’s study (2009), more research has to be done 
to conclude whether physical activity and diet restriction combined with leptin administration is a 
valuable treatment for obesity. 
 Just as in the previous study done by Zelissen, et al., (2005) in which the use of recombi-
nant leptin was used to determine its affect on weight loss, the following study (Hukshorn, et al., 
2002) was done using pegylated recombinant leptin (PEG-OB) to examine if its administration 
will decrease food intake and promote weight loss. Twenty-eight obese subjects, 16 women and 
12 men, partook in the study. Subjects were between the ages of 18-65 years and women had to be 
either sterile or postmenopausal. Anyone with a medical condition requiring pharmaceutical treat-
ment was excluded. After a 4 week lead in diet, only those who lost 1.75 kg or more were allowed 
to continue treatment. Treatment consisted of 60 mg pegylated recombinant leptin or a matching 
placebo, which was administered once a week over 8 weeks. In addition to the injections, subjects 
were on a hypoenergetic diet designed to reduce energy intake by 3200kJ/day. Body weight and 
height were measured weekly, as well as the BMI. Blood and urine were collected throughout the 
study. The results after 8 weeks were similar in the pegylated recombinant leptin group and the pla-
cebo. Both groups lost about the same amount of weight, and no real difference in change of BMI 
between the two groups was recorded. There was also no significant difference in the decrease 
of cholesterol, triglycerides, glucose and insulin levels between the treatment groups. However, 
pegylated recombinant leptin levels and total leptin levels showed an increase a week after the last 
dose. These results show that exposure to 60 mg of PEG-OB weekly for 8 weeks did not influence 
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weight loss in obese subjects, even though pegylated recombinant leptin levels were elevated after 
the study. Although this dosage of PEG-OB was ineffective, it may be possible that when PEG-OB 
is administered during a severe energy restriction or total leptin deficiency, it will cause weight 
loss. In addition, the small number of subjects studied, as well as the short duration of the study, 
may also explain the lack of effectiveness of pegylated recombinant leptin administration (Huk-
shorn, et al., 2002). It is interesting that the pegylated recombinant leptin did not produce a weight 
loss, while gene transfer in a viral vector did contribute to an increase in leptin levels and weight 
loss.
The Effect of Sleep on Ghrelin and Leptin
 Average sleep duration in the United States has declined over the past several decades. At 
the same time, obesity rates have increased. Studies indicate that sleep may regulate hunger and 
satiety through hormones including ghrelin and leptin. Previous studies have indicated that sleep 
deprivation leads to an increase in ghrelin and a decrease in leptin, which affects appetite and 
hunger. It is hypothesized that sleep brings about these changes by changes in the hypothalamic 
control of autonomic nervous system activity which influence ghrelin and leptin secretion. 
 A study was done (Littman, et al., 2007) on moderate to intense physically active post 
menopausal women to establish the relationship between exercise, sleep, BMI, ghrelin, leptin, and 
weight change over a 12 month period. Before the experiment, the scientists hypothesized what the 
outcome would be.
1. Improvement in sleep might lead to greater weight loss by influencing satiety and hunger hor-
mones.
2. Exercise induced decreases in leptin and increases in ghrelin would be greater in those whose 
sleep worsened as compared to those whose sleep remained the same or improved.
 Participants in the study were aged 50-75 years who exercised less than 60min/week of 
moderate or vigorous activity. Participant’s BMI had to be greater than 25.0 kg/m2. The exercise 
group had 87 subjects, while the control group contained 86. Blood was taken after a 12 hour 
overnight fast at the baseline, 3 months, and 12 months. Participants in the experimental group 
performed a minimum of 45 minutes of moderate to intense aerobic exercise 5 days a week for 
12 months. Those in the control group attended a 45 minute session of stretching once a week for 
a year. Subjects in both groups maintained their usual diet. The results revealed that the average 
BMI in women who slept more than 9 hours per night was higher than that of women who slept 8 
or fewer hours per night. Ghrelin levels increased during the 12 month trial among both groups. 
This increase was mainly due to weight loss. The difference in ghrelin levels was greater in those 
who experienced improved sleep as opposed to those whose sleep remained the same. Leptin de-
creased more among the exercise group than the control group. Leptin increased with worsening 
of sleep quality in the experimental group. The difference in leptin levels in both groups was less 
among those with improved sleep quality. The observed trends were in the opposite direction of 
the proposed hypothesis. The weight loss difference between the groups was greater for those who 
slept less. Ghrelin levels increased and leptin levels decreased among those with improved sleep 
compared with those with decreased sleep quality. In addition, exercise induced weight loss was 
greater in those who slept < 6 hours per night in direct opposition to the hypothesis that improved 
sleep would increase weight loss (Littman, et al., 2007).
 On the other hand, recent studies have shown that short sleep duration not only increases 
BMI, but also reduces circulating leptin levels which suppress appetite and increase ghrelin levels 
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that promote hunger. Experiments on subjects who slept 4 hours in comparison to 10 hours for two 
consecutive nights revealed that they experienced decreased leptin levels and increased ghrelin 
levels, overall increasing feelings of hunger and appetite. To further determine the influence of 
short term sleep curtailment on leptin and ghrelin secretion, fasting morning levels of these hor-
mones were taken from healthy men after nights of different amounts of sleep. 
 The study was done (Schmid, et al., 2008) on nine men whose ages ranged from 20- 40 
years. The BMI of these subjects fell between 20.7 and 25 kg/m2. Subjects had normal sleep cycles 
and were not following any particular diet. Average sleep was 7-8 hours with bedtime between 
10:00pm-1:00am and waking time 6:00-8:00am. Subjects were examined after three conditions, 
spaced 2 weeks apart. 1) a night of total sleep deprivation. 2) a sleep restriction to 4.5 hours during 
the first part of the night. 3) a night with 7 hours of sleep. Participants in the study did not drink 
caffeine for 10 hours before and alcohol for 24 hours before the experiment. In addition, subjects 
were told to avoid intense physical activity. Blood samples were taken, and then subjects rated 
their feelings of hunger on a scale from 0 (not at all) to 9 (severely). 
 Results showed (Figure 7) that subjects had 
stronger feelings of hunger after total sleep deprivation 
than after 7 hours or 4.5 hours of sleep. The difference 
between 7 and 4.5 hours in hunger ratings was not sig-
nificant. Ghrelin levels were 22 + 10% higher after total 
sleep deprivation than after 7 hours of sleep. After 4.5 
hours of sleep, ghrelin levels were increased 11 + 5%. 
Interestingly, leptin levels were completely unaffected 
by sleep restriction or deprivation. A single night of sleep 
deprivation increased feelings of hunger and plasma lev-
els of the hunger-promoting hormone ghrelin (Schmid, 
et al., 2008). There are still factors that have to be taken 
into account and further researched. What would be the 
effect of sleep deprivation and restriction on women? In 
addition, this study was done only over a short period 
of time and after one night of each category of sleep re-
striction. The question still remains, what effect will long 
term sleep deprivation have on ghrelin levels as well as 
leptin levels? 
 In the study done by Littman, et al. (2007), leptin 
levels did decrease in those that experienced less sleep, 
while in the study done by Schmid, et al., (2008), leptin 
levels were unaffected by sleep change. It is possible 
that the physical activity done by subjects in the former 
experiment was the driving factor behind the change in 
leptin levels, and not actual change in sleep. It is unclear, since sleep and exercise were combined 
into one experiment. Furthermore, the changes in ghrelin levels show an opposite trend in the two 
studies. In Littman, et al., (2007), ghrelin levels increased with improved sleep, while in Schmid, 
et al., (2008), ghrelin levels increased when subjects experienced less sleep.
 Obstructive sleep apnea syndrome, (OSAS) is a common disease associated with obese 
subjects. The actual effect of obstructive sleep on ghrelin and leptin levels is further complicated 
Figure 7. (Schmid, et al., 2008).
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by the following study whose results seem to differ from the research done by Littman, et al. 
(2007) and Schmid, et al. (2008). The subjects of the study were 65 obese men with obstructive 
sleep apnea syndrome. Subjects underwent polysomnography overnight to measure the degree 
of obstructive sleep. All subjects had fasting blood samples taken between 7:00-8:00 AM. Cho-
lesterol, triglyceride, leptin, and ghrelin levels were tested. Thirty of the 65 obese subjects had 
moderate to severe obstructive sleep apnea syndrome. Twenty two subjects did not have OSAS 
and became the control group. The results showed that leptin levels were higher in patients with 
moderate-severe obstructive sleep apnea syndrome compared to the control group. There was no 
difference in ghrelin levels between the two groups; however, ghrelin levels were correlated with 
BMI, while leptin levels were not (Ciftci, et al., 2005). This study is another factor pointing to the 
relationship of sleep, obesity, and corresponding ghrelin and leptin levels.
CONCLUSION
 Leptin and ghrelin both play major roles in energy balance in humans. It is unclear whether 
abnormalities in the leptin or ghrelin systems contribute to the development of obesity. However, 
disturbances in these systems do maintain obesity. Obese patients are leptin resistant, and it is 
therefore necessary to develop a treatment that overcomes it or bypasses normal leptin function-
ing. Ghrelin also is seen as a potential drug target for weight regulation, as obese patients are 
ghrelin-sensitive. Diet and exercise have significant effects on energy homeostasis. The use of 
therapeutic drugs alone is not sufficient to treat obesity. As seen from a number of experiments, 
the most effective treatment is provided by a combination of diet and exercise. The best strategy to 
accomplish long term changes in body weight is the use of potential anti-obesity agents in combi-
nation with a low fat diet and sufficient exercise. 
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